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NATIONAL CENTER FOR PREPAREDNESS, DETECTION, AND

CONTROL OF INFECTIOUS DISEASES (CVK)

The National Center for Preparedness, Detection, and Control of Infectious Diseases 
(NCPDCID) maximizes prevention, preparedness, and response to infectious diseases in order to 
protect populations domestically and internationally through leadership, partnerships, 
epidemiologic and laboratory studies, and the use of quality systems, standards, and practices. In 
carrying out its mission, NCPDCID: (1) Works collaboratively across CDC and with public 
health and healthcare partners in conducting, coordinating, and supporting surveillance, research, 
and prevention programs to prevent and minimize morbidity and mortality among domestic and 
international populations; (2) collaborates with other CDC programs to ensure availability of 
appropriate domestic and international platforms intended to build capacity and conduct public 
health work on infectious diseases; (3) coordinates activities across CCID and CDC related to 
vulnerable populations, healthcare quality, quarantine, research, surveillance, emerging 
infectious diseases, and laboratory services; (4) establishes relationships and partnerships with 
domestic and international health organizations, healthcare facilities, federal agencies, state and 
local health departments, and other external partners; (5) provides technical assistance to external 
partnerships for improving program operations; (6) provides a platform for synthesis, translation, 
and dissemination of research findings into public health practice at the front line; 
(7) participates in the development of national policies and guidelines for prevention and control 
of infectious diseases; (8) coordinates processes for developing, awarding, and managing grants 
and cooperative agreements; (9) administers a national quarantine program to protect the U.S. 
against the introduction of diseases from foreign countries and the transmission of communicable 
disease between states; (10) facilitates appropriate cross-cutting collaboration with other NCs, 
CCID, other CDC programs, and external partners to promote effective surveillance for 
infectious threats to health; (11) designs and conducts epidemiologic studies to investigate the 
causes and risk factors for infectious diseases; (12) identifies, evaluates, and promotes the 
nationwide implementation of interventions designed to prevent infectious diseases, 
antimicrobial resistance, related adverse events, and medical errors among patients and 
healthcare personnel; (13) investigates and responds to outbreaks, emerging infections, and 
related adverse events among patients, healthcare providers, and others associated with the 
healthcare environment; (14) leads the improvement of domestic and international laboratory 
practices in clinical and public health laboratories through a quality systems approach; 
(15) provides services and expertise in development of quality systems to support compliance 
with FDA regulations on production, distribution, and use of laboratory diagnostic reagents; 
(16) provides support to CDC laboratories and investigators including provision of animals, 
services, materials, and specialized expertise; and (17) provides emergency response 
coordination of CCID resources and enhanced epidemiologic, surveillance, and laboratory 
response capacity for bioterrorism and other infectious disease public health emergencies. 
(Approved 3/22/2007) 
Office of the Director (CVK1) 
(1) Directs and manages the science, programs and activities of the NCPDCID; (2) provides 
leadership and coordination for the development and implementation of programs to enhance 
the prevention and control of infectious diseases nationally and internationally; (3) provides 
leadership and guidance on policy, program planning and development, program integration, 
management, and operations; (4) identifies and coordinates synergies between national centers 
and relevant partners; (5) provides technical information services to facilitate dissemination of 
relevant public health information; (6) provides liaison with other Governmental agencies and 
international organizations; (7) coordinates, in collaboration with the appropriate CCID and CDC 
components, international health activities relating to the prevention and control of infectious 
diseases; (8) advises the Director CCID and the Director, CDC, on policy matters concerning 
NCPDCID programs and activities; (9) coordinates development and review of regulatory 
documents and congressional reports; (10) analyzes health programs and proposed legislation 
with respect to NCPDCID programs, goals and objectives; and (11) serves as primary liaison 
between NCPDCID and the National Center for Health Marketing on communications and 
marketing science, and its associated research and practice. (Approved 4/2/2008) 
Division of Bioterrorism Preparedness and Response (CVKB) 
The Division of Bioterrorism Preparedness and Response (DBPR) strengthens the ability of CDC 
and its partners to preserve the health and quality of life of communities by providing public 
health leadership and support to prepare and respond to bioterrorism and other public health 
infectious disease emergencies. In carrying out its mission, DBPR: (1) Provides the agency’s 
initial rapid response capabilities (epidemiology, surveillance, and laboratory) for bioterrorism 
and other infectious disease emergencies with 24-hour on-call status; (2) addresses the scientific 
and response planning and preparedness issues for bioterrorism and infectious diseases on a daily 
basis; (3) provides primary emergency response coordination and epidemiological, surveillance, 
and laboratory support to other divisions within CCID and the National Center for 
Environmental Health during responses to non-terrorism-related infectious disease outbreaks or 
public health emergencies; (4) maintains primary responsibility for the development and 
management of the Laboratory Response Network (LRN), a national network of public health 
and other laboratories with enhanced diagnostic capabilities for biological agents of concern, and 
which serves as the laboratory testing component of the BioWatch System established by the 
Department of Homeland Security; (5) supports the development, deployment, and quality 
control of diagnostic reagents to the LRN laboratories; (6) serves as a primary screening 
laboratory for CDC for specimens that may contain bioterrorism agents of concern; (7) provides 
primary CDC lab and epi/surveillance support for planning and assistance with National Security 
Special Events; (8) provides technical assistance to public health and other partners regarding 
bioterrorism detection and response; (9) develops and implements drop-in surveillance, analysis, 
and operational tools; (10) develops and maintains INDs and EUAs for unlicensed 
pharmaceutical components identified for use in a bioterrorism event; (11) provides primary 
CDC/CCID subject matter expertise for smallpox and supporting subject matter expertise for 
other potential bioterrorism agents; (12) leverages CDC, CCID, and other federal agency 
partnerships and subject matter expert resources to assist with these activities; and 
(13) coordinates activities with CCID, CDC, and other national and international governmental 
organizations. (Approved 3/22/2007) 
Office of the Director (CVKB1) 
Manages, directs, and coordinates the activities of the DBPR; (2) provides leadership and 
guidance on policy, program planning and development, program management, and operations; 
(3) provides DBPR-wide administrative and program services and coordinates or ensures 
coordination with the appropriate NCPDCID, CCID, and CDC offices on administrative and 
program matters; (4) provides liaison with other governmental agencies, international 
organizations, and other outside groups; (5) coordinates, in collaboration with the appropriate 
NCPDCID, CCID, Coordinating Office of Terrorism Preparedness and Emergency Response 
(COTPER), and CDC components, preparedness and response activities relating to bioterrorism 
and other public health infectious disease emergencies; and (6) advises the Directors of 
NCPDCID, CCID, and COTPER, on policy matters concerning DBPR activities. (Approved 
4/11/2007) 
Epidemiology Surveillance and Response Branch (CVKBB) 
(1) Rapidly responds to bioterrorism events, public health threats or infectious disease 
emergencies in unique collaboration with DBPR clinical and laboratory partners; (2) assists state 
and local partners in epidemiologic preparedness and outbreak detection through implementation 
of technical applications and scientific consultation; (3) provides subject matter expertise, 
recommendations and guidelines, and a scientific basis for CDC and National epidemiologic 
response protocols and surveillance methods; (4) assists in the development and maintenance of 
investigational new drug protocols and emergency use authorizations for vaccinations, 
treatments and prophylaxis of selected bioterrorist agents; (5) provides clinical review and 
support of bioterrorism-specific issues; (6) develops and manages the concept of operation for 
bioterrorism response plans; (7) provides primary scientific input into the identification and 
prioritization of CDC biological agents of public health concern for bioterrorism; (8) provides 
up-to-date education and training to local, state, federal, and international partners on 
bioterrorism and infectious disease emergency response and surveillance; and (9) provides 
epidemiologic, surveillance, and clinical technical consultation for bioterrorism and infectious 
disease preparedness for the cooperative agreement on Public Health Emergency Preparedness. 
(Approved 4/11/2007) 
Laboratory Response Branch (CVKBC) 
(1) Provides overall coordination for CDC and interagency bioterrorism laboratory program 
development; (2) provides leadership for the development of national priorities and policies 
involving bioterrorism laboratory issues; (3) provides technical assistance and guidance to public 
health laboratories funded through CDC's cooperative agreement for Bioterrorism Preparedness 
(Focus Area C); (4) provides leadership for the LRN in collaboration with the Association of 
Public Health Laboratories; (5) develops and disseminate protocols for specimen handling and 
LRN for Bioterrorism; (6) ensures reagent production, validation, and distribution to member 
laboratories of the LRN; (7) provides for the development and conduct of training courses 
appropriate for laboratory workers at both Sentinel and Reference LRN levels; (8) implements a 
proficiency testing program for critical agents for LRN member laboratories; (9) validates 
advanced technology for the identification and characterization of agents of bioterrorism; 
(10) provide laboratory triage capability at CDC for unknown biological and chemical agents; 
and (11) maintains rapid response readiness for personnel and equipment required to respond to a 
suspected bioterrorism event. (Approved 4/11/2007) 
Division of Global Migration and Quarantine (CVKC) 
(1) Administers a national quarantine program to protect the U.S. against the introduction of 
diseases from foreign countries and the transmission of communicable disease between states; 
(2) administers an overseas program for the medical examination of immigrants, refugees, and as 
necessary, other migrant populations destined for legal entry to the U.S., with inadmissible 
health conditions that would pose a threat to public health and impose a burden on public health 
and hospital facilities; (3) conducts surveillance, research, and prevention programs to prevent 
minimize morbidity and mortality among the globally mobile populations entering and leaving 
the U.S.; (4) maintains liaison with other federal agencies, state and local health departments, 
and other stake holders, and provides information on global migration and quarantine matters to 
them; (5) provides liaison with international health organizations and participates in the 
development of international agreements affecting quarantine; (6) evaluates and provides 
technical support on the development and enforcement of policies necessary for implementation 
of federal quarantine authority; (7) conducts studies to provide new information about health 
hazards abroad, measures for their prevention, and the potential threat of disease introduction 
into the U.S.; and (8) provides logistic support to other programs of the CDC in the distribution 
of requested biological agents and movement of biological specimens through U.S. ports of 
entry. (Approved 3/22/2007) 
Office of the Director (CVKC1) 
(1) Manages, directs, and coordinates the activities of the division; (2) provides leadership in 
development of division policy, program planning, implementation, and evaluation; (3) identifies 
needs and resources for new initiatives and assigns responsibilities for their development; 
(4) coordinates liaison with other federal agencies, state and local health departments, and 
interested industries; (5) coordinates liaison with international health organizations; and 
(6) reviews and evaluates all administrative services for both headquarters and Quarantine 
Stations and provides policy procedures and guidance on such matters. (Approved 4/11/2007) 
Quarantine and Border Health Services Branch (CVKCB) 
(1) Develops and implements strategies to monitor for diseases of public health interest arriving 
persons, animals, cargo, and conveyances at ports of entry to the U.S. and its possessions; 
(2) evaluates and revises public health preparedness activities at airports, seaports, and land 
crossings in the U.S. and its possessions; (3) reviews operations to assure the effective 
application of scientific data in implementing programs to monitor the importation of 
quarantinable and other specified diseases; (4) develops and initiates surveillance and other 
public health activities at sea, air, and land ports of entry to the U.S. and its possessions; 
(5) trains and supervises field staff in the epidemiological, technical, management, and 
administrative aspects of quarantine operations; (6) works cooperatively with other agencies and 
organizations in the U.S. and abroad to implement, improve, and enhance division activities at 
ports of entry to the U.S. and its possessions; (7) provides technical consultation and public 
health training to federal inspection services to implement the division’s activities, apply CDC 
regulations on quarantine, and ensure appropriate occupational safety and health protection for 
their staff; (8) collaborates with state and local health departments to prevent transmission and 
spread of quarantinable diseases and other diseases of public health significance associated with 
travel; (9) monitors arriving immigrants and refugees at ports of entry to the U.S. and its 
possessions and notifies state health departments on identified health conditions; (10) provides 
logistic support to other CDC programs and expedites the movement of persons, clinical 
specimens, lifesaving medications, and other materials through federal security; (11) serves as 
CDC’s representative at U.S. ports of entry for operational issues related to bio security and 
emerging infections; and 12) administers Deratting Certification program. (Approved 
4/11/2007) 
Immigrant Refugee and Migrant Health Branch (CVKCC) 
(1) Develops and maintains surveillance systems for infectious diseases among resettlement in 
the U.S.; (2) conducts infectious disease surveillance and epidemiological investigations in 
communities along the U.S.-Mexico border; (3) recommends appropriate, effective intervention, 
and prevention strategies to decrease morbidity and mortality among globally mobile populations 
and to prevent entry of disease into the U.S.; (4) performs epidemiologic investigations and 
scientific research projects related to health issues for immigrant, refugee, and migrant 
populations; (5) develops, reviews, and evaluates operations in the U.S. and abroad involving 
immigrant and refugee medical examination activities; (6) conducts enhanced refugee medical 
screening examinations; (7) responds to refugee resettlement emergencies; (8) conducts a 
continuing review of medical screening procedures to assure the most effective application of 
current medical practices; administers and monitors activities related to the overseas and 
domestic medical examinations of immigrants and refugees, convening boards of medical 
officers to reexamine immigrants and refugees, when necessary, and preparing, publishing, and 
distributing manuals for examining physicians; (9) works cooperatively and in concert with other 
federal and international agencies, voluntary agencies, and foreign governments, both in the U.S. 
and abroad, in administering the immigrant and refugee medical screening program; 
(10) establishes, maintains, and evaluates medical inspection and notification procedures 
regarding immigrants and refugees, providing coordination and liaison with local and state health 
departments on the follow-up of those with serious disease or mental problems, in particular 
notifiable diseases such as tuberculosis; (11) establishes and maintains procedures to process 
requests for waivers of inadmissible medical conditions; (12) provides scientific and technical 
support to the operation and regulatory responsibilities of the division; and (13) provides liaison 
and coordination of efforts with counterparts in other divisions and centers of CDC, as well as 
national and international agencies involved in addressing and preventing infectious diseases 
among globally mobile populations. (Approved 4/11/2007) 
Geographic Medicine and Health Promotion Branch (CVKCD) 
(1) Through the GeoSentinel Network, develops geographic-specific infectious disease risk 
profiles among mobile populations; (2) coordinates and provides immunization data and 
recommends appropriate and effective intervention and prevention strategies to decrease 
morbidity and mortality among international travelers; (3) develops and issues vaccination 
documents and validation stamps in accordance with the International Health Regulations; 
(4) conducts surveillance for and assists in investigations of adverse events following 
administration of traveler vaccines; (5) alerts appropriate disease-specific CDC programs about 
possible imported cases of disease and supports the relevant program to investigate these events; 
(6) monitors and analyzes reports of health threats overseas and issues travel notices, alerts, and 
advisories when appropriate; (7) notifies WHO of the incidence of quarantinable diseases in the 
U.S., as required by the International Health Regulations; (8) inspects shipments of nonhuman 
primates to ensure compliance with CDC regulations regarding quarantine, conditions of 
shipment and occupational safety and health of employees exposed to primates; (9) works to 
decrease the risk of importing zoonotic diseases of public health significance to humans via 
animals and cargo; (10) performs epidemiologic investigations and scientific research projects 
among U.S. travelers and imported animals; (11) periodically conducts active surveillance for 
infectious diseases among imported animals; (12) provides scientific and technical support to the 
operation and regulatory responsibilities of the division; and (13) provides liaison and 
coordination of efforts with counterparts in other divisions of CDC, state and local health 
authorities, the travel industry, as well as national and international agencies involved in 
addressing and preventing infectious diseases among international travelers and translocated 
animals. (Approved 4/11/2007) 
Division of Healthcare Quality Promotion (CVKD) 
The mission of the Division of Healthcare Quality Promotion (DHQP) is to protect patients; 
protect healthcare personnel; and promote safety, quality, and value in both national and 
international healthcare delivery systems. In carrying out its mission, DHQP: (1) Measures, 
validates, interprets, and responds to data relevant to healthcare processes and outcomes, 
healthcare-associated infections, antimicrobial resistance, adverse drug events, and other related 
adverse events or medical errors in healthcare affecting patients and healthcare personnel; 
(2) investigates and responds to emerging infections and related adverse events among patients 
and healthcare providers, or others associated with the healthcare environment; (3) collaborates 
with academic and public health partners to design, develop, and evaluate the efficacy of 
interventions for preventing infections and reducing antimicrobial resistance, and related adverse 
events or medical errors; (4) develops and disseminates evidence-based guidelines and 
recommendations to prevent and control healthcare-associated infections/antimicrobial 
resistance, and related adverse events or medical errors; (5) promotes the nationwide 
implementation of Healthcare Infection Control Practices Advisory Committee (HICPAC) 
recommendations and other evidence-based interventions to prevent healthcare-associated 
infections, antimicrobial resistance, and related adverse events or medical errors among patients 
and healthcare personnel; evaluates the impact of these recommendations and interventions 
across the spectrum of healthcare delivery sites; (6) develops, implements, and evaluates the 
effectiveness and impact of interventions to prevent transmission of healthcare-associated human 
immunodeficiency virus (HIV) and other bloodborne pathogen infections; (7) develops and 
evaluates diagnostic instruments and novel laboratory tests to detect and characterize 
antimicrobial-resistant bacterial pathogens and the infections that they cause; (8) promotes high 
standards of water quality in healthcare settings and tests and assures the water quality for CCID 
laboratories; (9) conducts epidemiologic, and basic and applied laboratory research to identify 
new strategies to prevent infections/antimicrobial resistance, and related adverse events or 
medical errors, especially those associated with medical or surgical procedures, indwelling 
medical devices, contaminated products, dialysis, and water; (10) establishes evidence-based 
data for bioterrorism preparedness, and building and site remediation by performing laboratory 
research on surface sampling, detection of bacterial bioterrorist agents by non-culture methods, 
and rapid detection of antimicrobial resistance in category A and B bacterial bioterrorist agents; 
(11) serves as the National Reference Laboratory for the identification and antimicrobial 
susceptibility testing of staphylococci, anaerobic bacteria, and those gram-negative bacilli 
causing healthcare-associated infections; (12) develops and maintains the National Healthcare 
Safety Network (NHSN), a tool for monitoring healthcare-associated infections, for measuring 
healthcare outcomes and processes, and for monitoring healthcare worker vaccination and 
selected health measures in healthcare facilities; (13) continually assesses rates of infections 
caused by resistant-bacteria in the U.S. through active surveillance, review of national healthcare 
data sets, and laboratory surveillance programs; (14) promotes the integration of the healthcare 
delivery system in federal/state/local public health preparedness planning; (15) coordinates 
activities, guidance, and research related to infection control across the agency and with national 
and international partners; (16) collaborates with other CDC National Centers (NC) and partners 
to assure quality clinical microbiology laboratory practices through proficiency testing, 
educational programs, and training of personnel; (17) trains Epidemic Intelligence Service 
Officers and other trainees; (18) coordinates antimicrobial resistance activities at CDC; 
(19) represents CDC as co-chair of the federal Interagency Task Force on Antimicrobial 
Resistance; (20) works in a national leadership capacity with public and private organizations to 
enhance antimicrobial resistance prevention and control, surveillance and response, and applied 
research; (21) coordinates blood, organ, and other tissue safety at CDC; (22) represents CDC on 
the Advisory Committee on Blood Safety and Availability and the Advisory Committee on 
Organ Transplantation; and (23) works in a national leadership capacity with other public and 
private organizations to enhance blood, organ, and other tissue safety through coordination of 
investigation, prevention, response, surveillance, applied research, health communication, and 
public policy. (Approved 12/13/2007) 
Office of the Director (CVKD1) 
(1) Manages, directs, and coordinates the activities of the DHQP; (2) provides leadership and 
guidance on policy, communications/media, program planning and development, program 
management, and operations; (3) provides DHQP-wide administrative and program services and 
coordinates or ensures coordination with the appropriate NCs and CDC staff offices on 
administrative and program matters; (4) provides liaison with other governmental agencies, 
international organizations, and other outside groups; (5) coordinates, in collaboration with the 
appropriate NC and CDC components, global health activities relating to the prevention of 
healthcare-associated infections/antimicrobial resistance, and related adverse events or medical 
errors; (6) coordinates activities, guidance, and research related to infection control across the 
agency and with national and international partners; (7) works with other federal agencies, state 
governments, medical societies, and other public and private organizations to promote 
collaboration and to integrate healthcare preparedness in federal/state/local public health 
preparedness planning; (8) develops and conducts healthcare preparedness exercises and drills; 
(9) leads and staffs the Healthcare Delivery and the Infection Control/Clinical Care functional 
seats in the CDC Director’s Emergency Operations Center; (10) coordinates antimicrobial 
resistance activities at CDC and represents CDC as co-chair of the federal Interagency Task 
Force on Antimicrobial Resistance; (11) works with other agencies, state governments, medical 
societies, and other public and private organizations to enhance antimicrobial resistance 
prevention and control, surveillance and response, and applied research; (12) coordinates blood, 
organ, and other tissue safety at CDC and represents CDC on the Advisory Committee on Blood 
Safety and Availability and the Advisory Committee on Organ Transplantation; (13) works with 
other federal agencies, state governments, and other public and private organizations to enhance 
blood, organ, and other tissue safety through coordination of investigation, prevention, response, 
surveillance, applied research, health communication, and public policy; (14) coordinates 
vaccine safety activities at CDC; (15) leads CDC activities to monitor vaccine safety; (16) leads 
CDC’s scientific research to evaluate the safety of all currently available and new vaccines; 
(17) provides program and administrative support for HICPAC; and (18) advises the Director, 
NCPDCID, on policy matters concerning DHQP activities. (Approved 10/05/2009) 
Clinical and Environmental Microbiology Branch (CVKDB) 
(1) Collaborates with the Prevention and Response Branch to provide laboratory response to 
outbreaks and emerging threats associated with infections/antimicrobial resistance and related 
adverse events throughout the healthcare delivery system; (2) provides comprehensive laboratory 
support and expertise for investigations of recognized and emerging bacterial agents in 
healthcare settings; (3) develops methods to assess contamination of environmental surfaces with 
bacterial agents of bioterrorism, the effectiveness of various water treatment strategies to control 
the intentional introduction of agents of bioterrorism into municipal water systems, and develops 
molecular methods for rapid assessment of antimicrobial resistance in agents of bioterrorism; 
(4) investigates novel and emerging mechanisms of antimicrobial resistance among targeted 
pathogens found in healthcare settings; (5) detects the toxins/virulence factors of bacteria causing 
healthcare-associated infections to understand their transmission and pathogenicity; (6) conducts 
research in collaboration with partners to develop new, accurate methods of detecting 
antimicrobial resistance in bacteria and to improve reporting of antimicrobial susceptibility 
testing results to physicians to improve antimicrobial use; (7) conducts laboratory research to 
identify new strategies to prevent infections/antimicrobial resistance, related adverse events, and 
medical errors, especially those associated with invasive medical devices, contaminated 
products, dialysis, and water; (8) evaluates commercial microbial identification and antimicrobial 
susceptibility testing systems and products and facilitates their improvement to provide accurate 
patient test results; (9) provides leadership in reducing microbiology laboratory errors that affect 
patient outcomes by evaluating laboratory proficiency and promoting laboratory quality 
improvements; (10) investigates the role of biofilms, particularly those detected in indwelling 
medical devices and medical water systems, in medicine and public health, and identifies novel 
methods to eliminate colonization and biofilm formation on foreign bodies; (11) investigates the 
role of the water distribution systems in healthcare facilities in order to understand and prevent 
waterborne healthcare-associated infections; (12) provides expertise, research opportunities, 
training, and laboratory support for investigations of infections and related adverse events to 
those in other CDC NCs and to our partners in areas related to quality clinical microbiology 
laboratory practices, investigation of emerging pathogens, environmental microbiology and 
bioterrorism preparedness. (Approved 12/13/2007) 
Prevention and Response Branch (CVKDC) 
(1) Coordinates rapid and effective epidemiologic response to strategically selected outbreaks 
and emerging threats caused by healthcare-associated infections, related adverse healthcare 
events, related infections in the community, and antimicrobial resistance; communicates the 
results and findings of response activities with federal and state agencies in order to alert 
healthcare providers and educate the public to prevent similar adverse events in the future; 
(2) strategically supports local, state, national, and international efforts to prevent healthcare­
associated infections, related infections in the community, antimicrobial resistance, and related 
adverse events or medical errors using evidence-based recommendations and effective health 
communications strategies that enhance rapid and reliable information dissemination and 
exchange; (3) develops and/or evaluates the effectiveness of both experimental and applied 
interventions to prevent healthcare-associated infections, related infections in the community, 
antimicrobial resistance, blood borne virus transmission, and related adverse events or medical 
errors across the spectrum of healthcare delivery sites; (4) provides epidemiology support to 
laboratory branch for investigation and study of both recognized and emerging bacterial 
healthcare pathogens and related community pathogens, including antimicrobial resistant forms 
of these pathogens; (5) develops, promotes, and monitors implementation of 
guidelines/recommendations, and other proven interventions to prevent healthcare-associated 
infections, related infections in the community, blood-borne virus transmission, antimicrobial 
resistance, medical errors, and occupational infections/exposures among healthcare personnel; 
(6) develops and/or evaluates the effectiveness of both experimental and applied interventions to 
promote healthcare worker safety; (7) develops, promotes, and monitors implementation of 
interventions to prevent transmission of healthcare-associated HIV infections and conducts case 
investigations of occupational HIV infections; (8) conducts research, including applied 
epidemiologic and clinical, to prevent healthcare-associated infections and antimicrobial resistant 
infections; (9) provides expert consultation, guidance, and technical support to other branches in 
the division, across the agency, to domestic and international partners, and the U.S. public on the 
epidemiology and prevention of healthcare-associated infections, related community infections, 
antimicrobial resistance, and exposures/injuries among healthcare personnel; and (10) provides 
epidemiology support to clinical and environmental microbiology branch to identify new 
strategies to prevent adverse events due to infections associated with indwelling medical devices, 
contaminated products, dialysis, and water. (Approved 12/13/2007) 
Surveillance Branch (CVKDD) 
(1) Monitors and evaluates on the national level the extent, distribution, and impact of 
healthcare-associated infections, antimicrobial use and resistance, adverse drug events, 
healthcare worker safety events, and adherence to clinical processes and intervention programs 
designed to prevent or control adverse exposures or outcomes in healthcare; (2) provides 
leadership and consultative services for statistical methods and analysis to investigators in the 
Branch, Division, and other organizations responsible for surveillance, research studies, and 
prevention and control of healthcare-associated infections and other healthcare-associated 
adverse events; (3) improves methods and enables wider use of clinical performance 
measurements by healthcare facilities and public health entities for specific interventions and 
prevention strategies designed to safeguard patients and healthcare workers from risk exposures 
and adverse outcomes through collaborations with extramural partners; (4) collaborates with 
public and private sector partners to further standardize, integrate, and streamline systems by 
which healthcare organizations collect, manage, analyze, report, and respond to data on clinical 
guideline adherence, healthcare-associated infections, including transmission of multi-drug­
resistant organisms and other healthcare-associated adverse events; (5) coordinates, further 
develops, enables wider use, and maintains the NHSN, (a web-based system for healthcare 
facilities throughout the U.S. to collect and analyze their own data and share data with DHQP 
and other organizations on healthcare-associated adverse events and process-of-care measures) to 
obtain scientifically valid clinical performance indices and benchmarks that promote healthcare 
quality and value at the facility, state, and national levels; (6) conducts applied research to 
identify and develop innovative methods to detect and monitor healthcare-associated infections 
and antimicrobial resistance; (7) conducts special studies and provides national estimates of 
targeted, healthcare-associated adverse events, antimicrobial use and resistance patterns, and the 
extent to which prevention and control safeguards are in use to protect at-risk patients across the 
spectrum of healthcare delivery sites; and (8) uses NHSN and other data sources to conduct 
special studies and provide national estimates of targeted occupational illnesses and injuries 
among healthcare workers and the extent to which preventive safeguards are in use across the 
spectrum of healthcare delivery sites. (Approved 12/13/2007) 
Division of Scientific Resources (CVKE) 
The Division of Scientific Resources (DSR) provides products, services, and specialized 
expertise to CDC staff and activities in support of research and service activities. In carrying out 
its mission, DSR: (1) Provides animals, laboratory supplies, animal and human blood products, 
glassware, mammalian tissue cultures, microbiological media, special reagents, and other 
laboratory materials in support of research and service activities to laboratories and investigators 
at CDC; (2) develops and implements applied research programs to expand and enhance the use 
of animal models necessary to support research and diagnostic programs and to improve 
breeding and husbandry procedures; (3) conducts both basic and applied research in cell biology 
and in the expansion of tissue culture technology as a research and diagnostic tool for infectious 
disease activities; (4) provides services for laboratory investigators in protein and DNA synthesis 
and sequencing, genomic sequencing, microarrays, proteomics, and molecular modeling; 
(5) maintains a bank of serum and other biological specimens of epidemiological and special 
significance to CDC's research and diagnostic activities; (6) obtains and distributes experimental 
and orphaned vaccines, drugs, antisera, antitoxins, and immune globulins; (7) manages and 
distributes the inventory, maintains the computerized system database, and provides general 
technical service support for dispensing, lyophilizing, capping, and labeling CDC Reference 
Reagents; (8) receives, triages, processes, and distributes specimens to CDC laboratories for 
reference diagnostic testing, research studies, and epidemics and reports diagnostic test results to 
submitting organizations; (9) manages all CDC exports and ensures compliance with regulations 
and serves as CDC liaison with Department of Commerce for export related issues; 
(10) produces and distributes specialized reagents and kits for the detection of select agents to 
members of the LRN; (11) provides services and expertise in development of quality systems to 
support compliance with FDA regulations on production, distribution, and use of laboratory 
diagnostic reagents; (12) provides oversight, guidance, and training for CCID laboratories 
regulated by the CLIA; (13) provides liaison activities, resources, and expertise for inquiries 
related to animals and zoonotic diseases; and (14) provides a centralized activity for tracking 
requests for and distributing select agents to investigators outside of CDC in compliance with 
federal regulations. (Approved (3/22/2007) 
Office of the Director (CVKE1) 
(1) Manages, directs, and coordinates the activities of DSR; (2) provides leadership and guidance 
on policy, budget, program planning and development, program management, and operations; 
(3) provides DSR-wide administrative and program services and coordinates or ensures 
coordination with the appropriate NC, CCID, and CDC staff offices on administrative and 
program matters; (4) provides liaison with other governmental agencies, international 
organizations, and other outside groups; (5) coordinates, in collaboration with the appropriate 
NCs, CCID, and CDC components, laboratory activities relating to support of outbreak 
investigations or laboratory-based research including but not limited to specimen management, 
biological reagents, and laboratory supplies; (6) maintains a formulary of investigational and 
licensed drugs and biologicals that are distributed to approved physicians for the prevention, 
control, and/or treatment of rare, tropical, or exceptional diseases; (7) collaborates with the 
Division of Bioterrorism Preparedness and Response by developing, producing, packaging, 
storing and distributing diagnostic kits and reagents; (8) collaborates with CDC and external 
partners on research related to STD transmitted infections as chronic infectious diseases; and 
(9) advises the Director, NCPDCID, on policy matters concerning DSR activities. (Approved 
4/11/2007) 
Animal Resources Branch (CVKEB) 
(1) Acquires and distributes laboratory animals for research; (2) provides appropriate housing, 
husbandry, and psychological enrichment for all research animals; (3) provides veterinary 
services, including clinical and surgical support, for the laboratory animals; (4) develops SOPs 
for animal care and use in accordance with the policies established by the American Association 
for Accreditation of Laboratory Animal Care, the Animal Welfare Act, The Guide for the Care & 
Use of Laboratory Animals, and the CDC International Animal Care & Use Committee; 
(5) conducts applied research to improve the care and use of animals in research and collaborates 
on research projects that uses laboratory animals; (6) provides consultation and laboratory animal 
technology training to investigators, technical staff and animal care personnel; and (7) provides 
oversight, support and investigator training for the GRANITE protocol development and animal 
tracking database. (Approved 4/11/2007) 
Biologics Branch (CVKEC) 
(1) Establishes and practices quality control and assurance procedures to ensure high product 
quality and integrity in compliance with the FDA Quality System Regulation and Good 
Manufacturing Practices standards; (2) provides consultation and training to CDC laboratorians 
and extramural organizations on cell culture techniques, media production methods and related 
procedures; (3) conducts applied and basic research, independently and collaboratively, on 
problems related to mammalian cell cultures, cell biology, gene expression systems, specialized 
diagnostics, large-scale antibody and hybridoma production; (4) develops, produces, evaluates, 
or procures and distributes mammalian and insect cell cultures, cell lines, hybridomas, cell 
culture and microbiological media, chemical reagents, animal blood products and in vitro 
diagnostic products to CDC scientists for diagnostic and research purposes; (5) manages a bank 
of cell line cultures for use in diagnostic and research activities; (6) in collaboration with CDC 
laboratorians, develops new and improved hybridomas and reference diagnostic reagents; 
(7) provides dispensing, lyophilizing, capping, and labeling services for products prepared at 
CDC; and (8) provides and maintains bioreactor services for production, purification, and 
conjugation of antibodies and antigens. (Approved 4/11/2007) 
Biotechnology Core Facility Branch (CVKED) 
(1) Provides to CCID components the instrumentation and expertise required to develop, refine, 
and apply modern technologies for molecular diagnosis the agents of infectious diseases; 
(2) provides synthetic oligonucleotides useful in the genetic characterization of pathogens and 
their hosts and in the development of rapid diagnostic tests; (3) maintains state-of-the-art 
instrumentation for automated genomic sequence analysis and collaborates with CCID 
components to apply this technology to large-scale sequencing projects; (4) maintains 
instrumentation for, and provides expert help with, functional genomics studies involving 
microarray assay of gene expression and other array-based genetic analysis; (5) maintains 
instrumentation for, and provides expert help with, the physical-chemical characterization of 
proteins germane to infectious disease, including the identification of expressed proteins by mass 
spectrometric-based proteomics; (6) maintains instrumentation for, and provides expert help 
with, mass spectrometric-based methods of pathogen discovery and identification; (7) provides 
synthetic peptides to facilitate studies of antigen/antibody interactions and to aid in the 
formulation of synthetic vaccines; and (8) provides facilities, open to all CCID researchers, for 
computational analysis of data generated by genomic sequencing, gene expression experiments, 
proteomics, and phylogenetics, as well as for computer visualization and analysis of the 
structure of biological macromolecules. (Approved 4/11/2007) 
Specimen Management Branch (CVKEE) 
(1) Provides centralized specimen management services for diagnostic, reference, and outbreak 
investigations; (2) receives, triages, processes, and distributes specimens to CDC laboratories for 
reference diagnostic testing, research studies, and epidemics and reports diagnostic test results to 
submitting organizations; (3) provides controlled rate freezing for cells and tissues; (4) maintains 
a bank of serum and other biological specimens of epidemiological and special significance to 
CDC's research and diagnostic activities managing comprehensive inventory and tracking 
systems of specimen collections; (5) serves as central facility for acquisition and distribution of 
fresh human blood, blood products, and serum in bulk; (6) packages and ships infectious 
substances and other materials, ensuring compliance with regulations for shipping clinical 
specimens, infectious substances, and other materials; (7) manages all CDC exports and ensures 
compliance with regulations and serves as CDC liaison with Department of Commerce for 
export related issues; (8) provides consultation and training in specimen management services; 
and (9) provides oversight, guidance, and training for CCID laboratories regulated by CLIA. 
(Approved 4/11/2007) 
Laboratory Support Branch (CVKEG) 
(1) Coordinates technical services for laboratory activities of CDC programs including 
procurement, processing, and distribution of glassware and related items, laboratory waste 
decontamination and disposal, laundry services, laboratory equipment management and 
maintenance, and materiel management; (2) provides consultation and training in technical 
services; and (3) maintains laboratory water treatment systems to ensure quality of CDC reagent 
laboratory water. (Approved 4/11/2007) 
Division of Emerging Infections and Surveillance Systems (CVKG) 
The Division of Emerging Infections and Surveillance Services (DEISS) improves CDC’s public 
health capacity to respond to infectious diseases by ensuring the availability of appropriate 
domestic and international platforms for conducting infectious diseases work; promoting 
effective, standards-based surveillance for infectious diseases; and providing technical support 
intramurally and extramurally for building public health capacity for infectious diseases and 
improving program operations. In carrying out its mission, DEISS: (1) Facilitates appropriate 
cross-cutting collaboration across CCID, other CDC programs, and external partners to promote 
effective surveillance for infectious threats to health; (2) conducts surveillance of infectious 
diseases of and conditions that impact the health of all residents of the circumpolar regions with 
special emphasis on diseases of high incidence and concern among indigenous peoples of the 
regions; (3) provides program expertise, linkages, and evaluation for infectious disease aspects of 
biosurveillance; (4) provides technical assistance and support for infectious disease surveillance 
activities both intramurally and extramurally; (5) analyzes economic impact of infectious 
diseases in collaboration with other CCID programs; (6) collaborates with other CCID and CDC 
programs to ensure availability of appropriate domestic and international platforms intended to 
build capacity and conduct public health work on infectious diseases; (7) provides leadership and 
coordination for CCID fellowships and training programs; (8) provides a platform for synthesis, 
translation, and dissemination of research findings into public health practice at the front line; 
(9) provides a platform for conducting epidemiologic studies to investigate the causes and risk 
factors for infectious diseases among residents of the Arctic and sub-Arctic; (10) participates in 
the development of national policies and guidelines for prevention and control of infectious 
diseases; (11) serves as an advocate for health departments and other public health partners on 
issues related to infectious disease activities and resources; (12) provides technical assistance to 
states and localities for improving program operations; (13) serves as a key liaison and focal 
point for communications and coordination in working with CCID programs, the CCID SSPU on 
Global Health, and COGH on international platforms for public health response, research, and 
capacity-building (Emerging Infections and Global Disease Detection); (14) provides 
administrative and management support for domestic and international platforms for public 
health response, research, and capacity-building; (15) provides technical support and 
coordination for CCID SSPU on surveillance; (16) coordinates with CCID SBU processes for 
developing, awarding, and managing grants and cooperative agreements; (17) works closely with 
CCID OD and the CDC Office of Strategy and Innovation on development and management of 
CDC goals for emerging infectious diseases; (18) provides management and administrative 
support for extramural partnership cooperative agreements; (19) participates in the development 
of performance measurements for infectious diseases cooperative agreement programs; and 
(20) serves as a liaison/point of contact to assist grantees in identifying appropriate technical 
assistance from CDC personnel. (Approved 3/22/2007) 
Office of the Director (CVKG1) 
(1) Manages, directs, and coordinates the activities of DEISS; (2) provides leadership and 
guidance on policy, program planning and development, program management, and operations; 
(3) coordinates DEISS-wide administrative and program services with the appropriate NC, 
CC/CO, or agency staff offices on administrative and program matters; (4) provides liaison with 
other governmental agencies, international organizations, and other outside groups; and 
(5) advises the Director on policy matters concerning DEISS activities. (Approved 4/11/2007) 
Division of Laboratory Systems (CVKH) 
The Division of Laboratory Systems (DLS) maximizes the impact of domestic and international 
laboratory services on the quality of the public’s health and patient outcomes through a 
comprehensive and systematic approach of leadership, partnerships, and the use of quality 
systems, standards and practices. In carrying out its mission, DLS: (1) Provides leadership in 
the development and coordination of high-priority partnerships with the public health and 
clinical laboratory community and their affiliate organizations; (2) promotes excellence in 
laboratory practices by developing, evaluating, and implementing systems for measuring and 
assessing the status of laboratory quality; (3) leads and/or participates in the development of 
voluntary laboratory standards and guidelines; (4) manages the HHS CLIA Committee which 
provides scientific and technical advice and guidance to the Secretary on laboratory practice 
issues; (5) develops federal quality standards for the Nation’s clinical laboratories; (6) provides 
leadership in the development and execution of laboratory health systems research; (7) provides 
leadership in development of the National Laboratory System (NLS); (8) through the NLS, 
enhances the nation’s preparedness and response capabilities; (9) provides leadership and the 
resources to develop the National Laboratory Database (NLD); (10) leads the improvement of 
international laboratory practices through a quality systems approach, developing and 
implementing country-specific plans for improving laboratory capability and capacity; 
(11) provides leadership in the development and implementation of guidelines, standards, and 
training products in international settings; (12) collaborates with other CDC components, 
governmental agencies, private sector organizations and other outside groups on laboratory 
quality issues; and (13) provides a forum for exchange of general and timely information about 
laboratory practices. (Approved 3/22/2007) 
Office of the Director (CVKH1)(1) Assures management support in the selection, prioritization 
and implementation of CDC goals; (2) coordinates with other CDC NC ODs on program, 
administrative, and informational matters; (3) identifies and prioritizes laboratory partnerships; 
(4) develops division strategy and planning; (5) provides leadership and guidance on strategic 
planning, policy, program management and operations, and project priority planning and setting; 
(6) establishes division goals, objectives, and priorities, and coordinates division activities with 
other components of CDC and partners external to CDC; (7) monitors progress in the 
implementation of projects and achievement of objectives; (8) plans, allocates, and monitors 
resources; (9) establishes and supports the NLD; (10) manages, directs, and coordinates the 
laboratory health systems research agenda and activities of the division; (11) provides liaison 
with other CDC organizations, other governmental agencies, private sector organizations and 
other outside groups; and (12) provides scientific leadership and guidance to the division to 
assure highest scientific quality and professional standards. (Approved 4/11/2007) 
Laboratory Practice Evaluation and Genomics Branch (CVKHB) 
(1) Encourages the establishment and adoption of performance standards for laboratory practice; 
(2) develops, evaluates, and implements systems for measuring and assessing laboratory quality; 
(3) facilitates and conducts research and demonstration projects to support the scientific 
development of performance standards, evaluation systems, and regulatory standards, and to 
assess the efficacy of established standards; (4) develops, promotes, implements, and evaluates 
intervention strategies to correct general performance deficiencies in health laboratory systems 
and worker competencies; (5) provides a forum for exchange of information about laboratory 
practice and research and development activities to promote the coordination of federal, state, 
and clinical laboratory improvement efforts; (6) coordinates and conducts activities that provide 
technical and scientific support to the Centers for Medicare and Medicaid Services (CMS) in its 
evaluation, development, and revision of standards and guidelines; (7) monitors and evaluates 
current and emerging practices in genomics to improve quality and promote access to genetics 
testing; and (8) collaborates with other components of the NCPDCID and CDC in carrying out 
the above functions. (Approved 4/11/2007) 
Laboratory Practice Standards Branch (CVKHC) 
(1) Encourages the establishment and adoption of mandatory and voluntary standards for 
laboratory practice; (2) assists CMS in the implementation of the CLIA; (3) coordinates and 
conducts standards development, validation, and review activities that provide support to CMS in 
its development and revision of the CLIA standards and guidelines; (4) provides technical 
assistance to CMS in its review of laboratory accreditation programs, state laboratory licensure 
programs, and proficiency testing programs; (5) provides technical assistance to CMS in 
responding to inquiries, especially pertaining to issues relating to testing complexity, personnel, 
quality control/quality assessment, and proficiency testing; (6) evaluates the applicability of 
CLIA quality standards to new laboratory technology and methodologies and, when necessary, 
assists in the establishment of appropriate alternative quality assurance measures; (7) performs 
review of CMS’s guidelines for CLIA program implementation and oversight; (8) provides 
scientific support for issues relative to the development and implementation of cytology 
standards; (9) assists in the development and review of voluntary laboratory performance 
standards and guidelines; (10) disseminates information about laboratory standards and practices; 
(11) provides materials, forums, briefings, and assistance to CDC and external organizations in 
the interpretation, understanding, and implementation of the CLIA regulations; and 
(12) collaborates with other components of CDC in carrying out the above functions. (Approved 
4/11/2007) 
Laboratory Systems Development Branch (CVKHD) 
(1) Improves access by state laboratories to information on their clinical laboratories (NLD); 
(2) defines and promotes best practices (performance standards and Healthy People 2010 
measures); (3) promotes the development of management and leadership skills among present 
and developing public health laboratory leaders; (4) improves communication and collaboration 
between state public health and clinical laboratories; (5) provides a forum for exchange of timely 
information about laboratory practice, especially as it relates to high priority public health issues; 
(6) researches the causes for failures to adopt voluntary laboratory practice guidelines; 
(7) provides consultation to state and larger local public health laboratories that request advice 
concerning issues ranging from management to physical surroundings; (8) promotes, develops, 
and implements training needs assessment methodology to establish priorities for training 
interventions; (9) develops and conducts training to facilitate the timely transfer of newly 
emerging laboratory technology and standards for laboratory practice; (10) provides technical 
assistance, consultation, and training for trainers to improve the capacity and capability of 
regional health organizations and agencies to develop and maintain decentralized training 
networks for laboratory professionals; (11) provides training and consultations concerning which 
laboratory equipment and reagents are most suited to infrastructure deprived settings; and 
(12) collaborates with other components of CDC in carrying out the above domestic and 
international functions. (Approved 4/11/2007) 
